Navigating Evolving Paradigms in B-cell Malignancies: Latest Insights and Novel Approaches for The Oncology Care Team

October 29, 2021

This series will review the role of the B-cell receptor pathway in the treatment of B-cell malignancies and explore the latest safety and efficacy data for novel, oral agents such as BTK inhibitors, PI3K inhibitors, and BCL-2 inhibitors.


Presented by Creative Educational Concepts, Inc. and accredited by the University of Cincinnati.

Supported through independent educational grants from AstraZeneca and Janssen.

Target Audience

Hematologists, oncologists, nurses, nurse practitioners, physician assistants, pharmacists, and all other allied health professionals of the hematology/oncology team.

Learning Objectives

  1. Outline the role of the B-cell receptor (BCR) pathway in the development of B-cell malignancies and identify enzymes downstream of the BCR that can serve as therapeutic agents.  
  2. Examine recent, top-line trial data for novel agents in the treatment of B-cell malignancies, including, BTK inhibitors, PI3K inhibitors, and BCL2 inhibitors.
  3. Analyze the most recent national guideline recommendations for the treatment of various B-cell malignancies and discuss the emerging role of novel agents into these treatment paradigms.
  4. Using a case-based approach, assess key issues in therapy selection, optimizing the use of novel therapies, managing adverse events, increasing patient adherence, and improving communication with both patients and with other members of the oncology care team.
     

Additional Information

AttachmentSize
PDF icon GR 10.29.21 Handout Updated.pdf7.4 MB
Course summary
Available credit: 
  • 1.00 ACPE Pharmacy
  • 1.00 AMA PRA Category 1 Credit™
  • 1.00 ANCC
  • 1.00 Participation
Course opens: 
08/17/2021
Course expires: 
11/30/2021
Event starts: 
10/29/2021 - 12:00pm
Event ends: 
10/29/2021 - 1:00pm
Rating: 
0

  5 min - Welcome and Introductions
10 min - The BCR Pathway: A Key Target in B-cell Malignancies 
25 min - Exploring Contemporary Treatment Approaches: Novel Agents in B-cell Malignancies 
15 min - Putting it into Practice: Patient Cases and Practical Strategies for Interprofessional Oncology Care Team
  5 min - Conclusion and Q&A

Live Virtual
Community Grand Rounds
United States

Loretta J. Nastoupil, MD
Department of Lymphoma – Myeloma
Division of Cancer Medicine
MD Anderson Cancer Center
Houston, TX

 

Loretta J. Nastoupil, MD is an Associate Professor in the Department of Lymphoma/Myeloma at the University of Texas MD Anderson Cancer Center in Houston, TX USA. Dr. Nastoupil received her medical degree from the University of Texas Southwestern Medical School and completed her Internal Medicine training at Washington University and Hematology/Medical Oncology fellowship at Emory University. She leads the indolent lymphoma and new drug development teams which are in line with her research interests of designing and conducting prospective trials aimed at exploiting the immune system to eradicate B-cell lymphoma. She is also interested in real world evidence and has been involved in exploring outcomes among patients treated with standard of care CAR T cell therapy.


Faculty Disclosure 
In accordance with the Food and Drug Administration, the speakers have disclosed that there is the potential for discussions concerning off-label uses of a commercial product/device during this educational activity.

Any person who may contribute to the content of this continuing education activity must disclose relevant relationships (and any known relationships of their spouse/partner) with commercial interests whose products or services are discussed in educational presentations. A commercial interest is defined as an entity producing, marketing, re-selling, or distributing health care goods or services consumed by, or used on patients. Relevant relationships include receiving from a commercial interest research grants, consultant fees, travel, other benefits, or having a self-managed equity interest in a company.

Disclosure of a relationship is not intended to suggest or condone any bias in any presentation but is made to provide participants with information that might be of potential importance to their evaluation of a presentation.

Planners
Vanessa Carranza, PharmD–has no relevant financial relationships to disclose in relation to the content of this activity.
Beth Faiman, PHD, CNP–has no relevant financial relationships to disclose in relation to the content of this activity.
Justin Horowitz, PharmD, BCOP–has no relevant financial relationships to disclose in relation to the content of this activity.
Sandra E. Kurtin, PhD, ANP-C, AOCN–has disclosed that she is a consultant for AbbVie, Amgen, Incyte, and Janssen.

Presenters 
John N. Allan, MD–has disclosed that he is a consultant for Abbvie, AstraZeneca, BeiGene, Epizyme, Genentech, Janssen, and PCYC. He receives grant/research support from BeiGene, Celgene, Genentech, Janssen, and TG Therapeutics and is on the speakers' bureau for Abbvie, BeiGene, and PCYC/Janssen.
Matthew S. Davids, MD–has disclosed that he is a consultant for AbbVie, Adaptive Biotechnologies, AstraZeneca, BeiGene, Eli Lilly, Genentech, Janssen, Merck, Pharmacyclics, Research to Practice, Takeda, TG Therapeutics, and Verastem Oncology, He receives grant/research support from AbbVie, Adaptive Biotechnologies, AstraZeneca, BeiGene, Eli Lilly, Genentech, Janssen, Merck, Pharmacyclics, Research to Practice, Takeda, TG Therapeutics, and Verastem Oncology.
Loretta J. Nastoupil, MD- has disclosed that she is a consultant for ADC therapeutics, Bayer, BMS/Celgene, Genentech, Epizyme, Janssen, Gilead, Morphosys and Norartis. She receives grant/research support from BMS/Celgene, Genentech, Epizyme, Gilead, Genentech, Novartis, Janssen, Pfizer and TG Therapeutics.
Stephen Spurgeon, MD–has disclosed that he is a consultant for Genentech, Innate Pharma, Kyropharma, and Velos-Bio.

Peer Reviewers 
Barb Forney–has no relevant financial relationships to disclose in relation to the content of this activity. 
Bruce Gebhardt, MD–has no relevant financial relationships to disclose in relation to the content of this activity.
Jeanie Patrick, PharmD–has no relevant financial relationships to disclose in relation to the content of this activity.
Stephen Spurgeon, MD–has disclosed that he is a consultant for Genentech, Innate Pharma, Kyropharma, and Velos-Bio.
 

Accreditation
This program has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of the University of Cincinnati and Creative Educational Concepts. The University of Cincinnati is accredited by the ACCME to provide continuing education for physicians. 

Medicine (ACCME)
The University of Cincinnati designates this live activity for a maximum of 1 AMA PRA Category Credit(s)TM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Pharmacy (ACPE)
This application-based activity is approved for 1.0 contact hour (.10 CEUs) of continuing pharmacy education credit (JA0007101-9999-21-008-L01-P)

Nursing (ANCC)
This activity is designated for 1.0 contact hour. 


Upon completion of a CE request form, statements of credit for physicians, physician assistants, and nurses will be issued within 30 business days. Pharmacy credit will be reported directly to the National Association of Boards of Pharmacy® (NABP®) CPE Monitor electronic CE tracking system.

Off-Label Disclosure Statement
Faculty members are required to inform the audience when they are discussing off-label, unapproved uses of devices and drugs.  Physicians should consult full prescribing information before using any product mentioned during this educational activity.

Learner Assurance Statement
The University of Cincinnati is committed to resolving all conflicts of interest issues that could arise as a result of prospective faculty members’ significant relationships with drug or device manufacturer(s).  The University of Cincinnati is committed to retaining only those speakers with financial interests that can be reconciled with the goals and educational integrity of the CME activity. 

Disclaimer Statement
The opinions expressed during the live activity are those of the faculty and do not necessarily represent the views of the University of Cincinnati. The information is presented for the purpose of advancing the attendees’ professional development.
 

Available Credit

  • 1.00 ACPE Pharmacy
  • 1.00 AMA PRA Category 1 Credit™
  • 1.00 ANCC
  • 1.00 Participation
Please login or register to take this course.